A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal Investigator
Joyce Liu, MD, MPH
Status
Closed to Accrual
Date Opened To Accrual
February 04 2016
Date Closed to Accrual
January 12 2018
Disease Site
Gynecologic [GY]
Ovarian
Phase
III
Developmental Therapeutics
No
Primary Objective
Assess the efficacy of either single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer
Patient Population
Patients have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers. Patients with known deleterious germline BRCA1 or BRCA2 mutation on a clinical assay with an ovarian, primary peritoneal, or fallopian tube cancer of the following other Mullerian histologies are also eligible: clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma.
Target Accrual
549
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.